In conclusion, for PWS with diabetes patients taking SGLT-2 inhibitors, ketonuria may be related to enhanced lipolysis, which should be carefully identified; and SGLT-2 inhibitors should not be easily withdrawn. This evidence concerns the gene SLC5A2 and Prader-Willi syndrome.